The Evaluation of Joint Detection of CA19-9, AFP and CEA in Identification and Diagnosis of Cholangiocarcinoma
Keywords:
cholangiocarcinoma - hepatocellular carcinoma - tumor markers - identification and diagnosis - ROC curveAbstract
Serum CA19-9 is most sensitive marker for diagnosis of cholangiocarcinoma. However it can be found varies in different types of liver cancer. In recent years, the joint detection of multiple tumor markers met the requirements of the elevating sensitivity and the high accuracy of diagnosis. There was no previous data collection at Chonburi hospital. The objective of this study is to explore the application of joint detection of serum CA19-9, AFP and CEA in identification and diagnosis of cholangiocarcinoma. This study was conducted during 1 January 2012 to 15 March 2019 at Chonburi Hospital in patients diagnosed cholangiocarcinoma and hepatocellular carcinoma (HCC) by histopathology confirmation.
In cholangiocarcinoma patients had levels of serum CA19-9 and CEA significantly higher than in HCC patients, whereas serum AFP was significantly lower. The area under ROC curve of single detection of serum CA19-9, AFP and CEA were 0.91, 0.13 and 0.72, which led to the optimal cut-off values at 136.00 U/ml, 39.79 ng/ml and 12.95 ng/ml respectively. In case use only CA19-9 marker gives accuracy 81.5%.The diagnostic effect of combined CA19-9, AFP and CEA was the highest at 87.7%.
Conclusions: To differentiate between cholangiocarcinoma and HCC, the joint detection of serum CA 19-9, AFP and CEA can help for diagnosis. A cut-off values for cholangiocarcinoma are serum CA19-9 more than 136.00 U/ml, AFP lower than 39.79 ng/ml and CEA more than 12.95 ng/ml, which provided sensitivity 88.2%, specificity 87.1% and accuracy 87.7%
References
Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehen-sive update, Part 1. Oncology 2004;18:889-96.
Green A, Uttaravichien T, Bhudhisawasdi V, Chartbanchachai W, Elkins DB, Marieng EO, et al. Cholangio-carcinoma in north east Thailand. A hospital-based study. Trop Geogr Med 1991;43:193-8.
Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosa-mine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 1978;38:4634-9.
Liu LK, Shao MW, Ma L, Sun J, Guan D, Shu Y. Values of seven tumor markers in the identification and diagnosis of esophageal carcinoma accompanied by neuroendocrine differentiation. J Int Transl Med 2015;3:39-43.
Chaiteerakij R, Harmsen WS, Marrero CR, Aboelsoud MM, Ndzengue A, Kaiya J, et al. A new clinically based staging system for perihilar cholangiocarcinoma. Am J Gastroenterol 2014;109:1881-90.
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholan-giocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95:204-7.
Tang X, Zhang J, Chen Y, Lan Z, Wang C. Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma. Chin J Oncol 2014;36:662-6.
Kim SW, Lim DH, Park HC, Park W, Park JO, Park YS. Salvage radiation therapy for isolated local recur-rence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. Ann Surg Oncol 2015;22:1308-14.
Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepato-cellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama 2002;56:317-20.
Li Y, Li DJ, Chen J, Liu W, Li JW, Jiang P. Application of joint detection of serum AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma. Asian Pac J Cancer Prev 2015;16:3451-5.
Nanashima A, Sumida Y, Abo T, Nagasaki T, Takeshita H, Fukuoka H, et al. Patient outcome and prognos-tic factors in intrahepatic cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2007;54:2337-42.
Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, Pitt HA. Biliary carcinoem-bryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996;171:147-53.
Sheen-Chen SM, Sun CK, Liu YW, Eng HL, Ko SF, Kuo CH. Extremely elevated CA19-9 in acute cholan-gitis. Dig Dis Sci 2007;52:3140-2.
Lumachi F, Lo Re G, Tozzoli R, D'Aurizio F, Facomer F, Chiara GB, Basso SM. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study. Anticancer Res 2014;34:6663-7.
Wayne WD. Biostatistics: a foundation for analysis in the health sciences. 6th ed. John Wiley & Sons; 1995.
Ngamjarus C, Chongsuvivatwong V. n4Studies: Sample size and power calculations for iOS. The Royal Golden Jubilee Ph.D. Program - The Thailand Research Fund&Prince of Songkla University 2014.
Vatanasapt V, Martin N, Sriplung S, Chindavijak K, Sontipong S, Sriampron H, et al. Cancer incidence in Thailand 1988-1991. Cancer Epidemiology, Biomarkers & Prevention 1995;4:475-83.
Downloads
Published
Versions
- 2026-02-13 (2)
- 2020-09-02 (1)
Issue
Section
License
Copyright (c) 2020 Chonburi Hospital Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี